Compare DexCom, Inc. (DXCM) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NRG Energy Inc — how do they compare? DexCom, Inc. trades at $83.66 (market cap $31.86B), while NRG Energy Inc trades at $107.12 (market cap $22.35B). The key difference: DexCom, Inc. is the larger of the two by market cap, and NRG Energy Inc pays a 1.79% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and NRG Energy Inc for 63 Days on average.
| DXCM | NRG | |
|---|---|---|
Market Cap | $31.86B | $22.35B |
Volume | 3,607,070 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $92.34 | $184.03 |
52-Week Low | $54.84 | $95.23 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $31.32B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
NRG Energy trades at $107.24, down 1.26% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with 26.77% ROE and 2.56% net margin, though recent Q1 and Q2 2026 earnings missed expectations. Revenue growth remains positive, reaching $30.71B in 2025, while valuation metrics show a P/E of 27.69 and P/S of 0.65. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant.
Outlook remains positive with analyst consensus strongly bullish (70% buy ratings) and a $202.90 price target suggesting significant upside. Key risks include rising debt levels (56.42% debt-to-asset ratio) and execution challenges on major capital projects. The company's dual retail/generation model provides stability, but investors should monitor earnings delivery against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
